Trial Purpose

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT03407144

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Patients that have an inadequate response to chemotherapy will receive study medication (pembrolizumab) in addition to continuing chemotherapy. Radiotherapy may or may not be an option.

Patients that have an adequate response to chemotherapy will not receive any further study treatment. Your study doctor will determine your next treatment per standard of care and will discuss this with you in more detail.

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date April 9, 2018
  • Estimated primary completion date February 13, 2027
  • Estimated study completion date February 13, 2027

Eligibility

Conditions Icon

Conditions

Hodgkin Lymphoma

Age Range Icon

Age Range

3 - 25

Sex Icon

Sex

All

Trial locations

What Can You Do Next?

If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.

Discuss Icon

Discuss With Your Doctor

Print this page or email it to your doctor to discuss at your next visit.

CLINICALTRIALS.GOV IDENTIFIER:

NCT03407144

When speaking to your doctor, please have the trial identifier number available.

Participating in a clinical trial is an important decision.

Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.